Publication | Closed Access

Treatment of β-thujaplicin counteracts di(2-ethylhexyl)phthalate (DEHP)-exposed vascular smooth muscle activation, inflammation and atherosclerosis progression

Vascular DiseaseCardiovascular DiseaseAtherosclerosis ProgressionVascular PharmacologyPhysiologyPharmacologyEndothelial DysfunctionVascular BiologyPharmacotherapyβ-Thujaplicin CounteractsMedicineAtherosclerosisDyslipidemiaOxidative Stress